Barclays Has Lowered Expectations for Cellectis (NASDAQ:CLLS) Stock Price
Cellectis (NASDAQ:CLLS – Get Free Report) had its target price lowered by Barclays from $5.00 to $4.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. Barclays‘s price objective points to a potential upside of 189.86% from the stock’s current […]
More Stories
How Advanced Browsers Limit Digital Tracking
As the online world evolves, digital privacy is becoming increasingly important. Many users now seek options beyond standard browsers. With...
Bilt Launches 3 New Credit Cards With 10 Percent Interest Cap for First Year
By Mary Prenon Bilt, one of America’s youngest credit card firms, founded in 2019, is launching a suite of three...
Trump Unveils New Health Care Affordability Plan
By Lawrence Wilson President Donald Trump on Jan. 15 released his administration’s new health care affordability plan, which aims to...
US, Denmark, Greenland to Form Working Group to Find Agreement on Island’s Future
By Ryan Morgam and Emel Akan WASHINGTON—Following a White House meeting on Jan. 14, the foreign ministers of Denmark and...
SEO for Manufacturing Companies: Strategies to Generate High-Quality Leads
SEO has become the biggest part of life in this competitive world. The efficient use of SEO can be done...
The USA “Needs Greenland for the Purpose of National Security”: Trump Remains Adamant
On 14 January, US President Donald Trump declared that “anything less than having Greenland in the hands of the United...